|
|||||
|
|
Clinical results of EGFR-targeted therapies in advanced colorectal cancer |
|
| Affiliation: | 1. INSERM U728 and Department of Medical Oncology, Beaujon University Hospital, AP-HP-PRES, Paris 7 Diderot, 100 boulevard du Général Leclerc, 92110 Clichy, France;2. Department of Gastroenterology and Pancreatology, Beaujon University Hospital, AP-HP-PRES, Paris 7 Diderot, 100 boulevard du Général Leclerc, 92110 Clichy, France;3. AAREC Filia Research, 1 place Paul Verlaine, 92100 Boulogne-Billancourt, France;4. Department of Pathology, Beaujon University Hospital, AP-HP-PRES, Paris 7 Diderot, 100 boulevard du Général Leclerc, 92110 Clichy, France |
| Abstract: | This paper is an updated review of the pre-clinical rationale and clinical results of new EGFR-targeted agents – cetuximab and panitumumab – employed in the management of advanced/ metastatic colorectal cancer. The addition of either biologic agent or last generation standard chemotherapy regimens – FOLFIRI and FOLFOX – has yielded better results as compared to those reported for chemotherapy alone. These results have been obtained without a significant increase in severe toxicity with the exception of skin side-effects. |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |